Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice post. Well done.
Been holding this one a while and finally sold.
I bought high and sold high.
Any yong fans have any predictions?
looks like an uptrend.
higher highs and higher lows.
Thanks for the info.
anyone have a price target. $5.75 - $6?
probaby never
I was hoping 1.7 was bottom.
might need to wait to buy some then.
These conferences are very important to get the word out on a future product as well as network with potential clients.
NovaBay Pharmaceuticals to Present at 2011 Biotech Showcase Conference
CEO Dr. Ron Najafi to Provide Corporate Presentation and Participate on Panel Addressing New Treatments for Infectious Diseases
EMERYVILLE, CA – January 7, 2011 – NovaBay Pharmaceuticals (NYSE Amex: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, will present at the 2011 Biotech Showcase Conference being held at the Parc 55 Wyndham San Francisco – Union Square. Dr. Ron Najafi, NovaBay’s Chief Executive Officer, will address attendees on Tuesday, January 11, 2011 at 11:00 AM Pacific Time.
Dr. Najafi will also participate in a panel discussion on the infectious disease landscape titled “Infectious Disease: A War on Many Fronts—Can It Be Won?”The panel discussion will take place on Wednesday, January 12, 2011 from 8:00 AM - 9:00 AM at the Parc 55 Wyndham Hotel.
Panel Discussion Overview:
On one front, viral infections have proven to be one of man’s toughest foes. While H1N1, H5N1 and SARS grab world headlines, the biotech industry is in an ongoing battle with HIV, hepatitis and the more exotic Ebola and dengue fever. On another front, bacterial infections are becoming more and more difficult to treat because of antibiotic resistance. While MRSA is best known, bacterial resistance is developing against every antibiotic in use today and solutions are still on the horizon. A panel of CEO’s developing an arsenal of next generation antiviral and antimicrobial weapons will discuss the infectious disease landscape and their technologies and targets.
More information about the 2011 Biotech Showcase Conference is available at http://www.ebdgroup.com/bts/index.php.
To arrange a meeting with NovaBay management, please contact Adam Holdsworth at 212-825-3210, or e-mail adam@investorrelationsgroup.com.
This one is important because it is forecasted to bring in millions in revenue.
NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422
Against Deadly “Superbug” producing
NDM-1 (New Delhi Metallo-beta-lactamase-1)
NVC-422 Also Shown Effective Against Six Other Highly Drug-Resistant Pathogens
EMERYVILLE, CA – January 6, 2011 – NovaBay Pharmaceuticals (NYSE Amex: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted at a third-party laboratory, NovaBay’s lead Aganocide, NVC-422 has shown in vitro activity against the “superbug” New Delhi Metallo-beta-lactamase-1 (NDM-1)-encoded Klebsiella pneumoniae at a very low concentration of 2 micrograms per milliliter. In comparison, Imipenem, which is a mainstay antibiotic for the treatment of antibiotic-resistant bacterial infections, is not effective against NDM-1-encoded strains.
NovaBay currently is engaged in testing additional strains of E. coli and K. pneumoniae encoded with NDM-1 gene. The company previously reported that NVC-422 was effective in vitro against resistance phenotypes of E. coli and K. pneumoniae, including extended-spectrum beta-lactamase (ESBL) and multidrug-resistant (MDR) strains. NovaBay intends to publish and present the full data set at the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
K. pneumoniae and E. coli have been identified as a cause of severe infections, sepsis and possibly death. In a number of non-systemic/topical opportunities of interest to NovaBay’s development, both these superbugs are major risk factors. These include catheter-associated urinary tract infections (UTIs); respiratory tract infections, including those caused by cystic fibrosis; and wound infections, including venous stasis, pressure ulcers and diabetic ulcers.
Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, said, “We were very excited to see the in vitro activity results of NVC-422 against NDM-1 strains. In fact, we have collected data indicating that NVC-422 is also effective in vitro against all six highly resistant pathogens know as ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter which are the cause of much of the hospital-associated infections today. We intend to translate this activity into products that will benefit patients in need. Both UTI and chronic non-healing wounds will be the future breeding ground for NDM-1 producing bacteria.”
NovaBay is currently engaged in a Phase 2 human trial for urinary catheter blockage and encrustation (UCBE) leading to urinary tract infections, and the company and its partner Galderma S.A. are engaged in the clinical development of its lead compound for the treatment of impetigo, a highly contagious infection with potential benefit in chronic wound care management.
About the NDM-1 gene
NDM-1 is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics. These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. The gene for NDM-1 is one member of a large gene family that encodes beta-lactamase enzymes called carbapenemases. Bacteria that produce carbapenemases are often referred to in the news media as "superbugs" because infections caused by them are difficult to treat.
NDM-1 was first detected in a Klebsiella pneumoniae isolate from a Swedish patient of Indian origin in 2008. It was later detected in bacteria in India, Pakistan, the United Kingdom, the United States, Canada, Japan and Brazil. The most common bacteria that make this enzyme are Gram negative such as Escherichia coli and Klebsiella pneumoniae, but the gene for NDM-1 can spread from one strain of bacteria to another by horizontal gene transfer.
...
NovaBay Pharmaceuticals and Galderma Expand Their Agreement to Include Impetigo
Agreement Increases Potential Milestones to $62 Million Plus Double-Digit Royalties on Future Sales
EMERYVILLE, Calif., Dec. 6, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide® compounds against impetigo, Galderma has agreed to exercise its option for this indication.
Dr. Ron Najafi, Chairman and CEO of NovaBay, commented, "We are very pleased with Galderma's decision to exercise their option. Galderma is the world's largest dermatology company with impressive clinical and commercial capabilities. This provides further evidence of Galderma's commitment to commercializing NovaBay's Aganocides for dermatological indications and we look forward to advancing these programs through clinical trials to commercialization."
Humberto C. Antunes, CEO of Galderma, commented, "This enhancement of our collaboration demonstrates our belief that NovaBay's first-in-class Aganocides have the potential to provide a significant advancement in the treatment of skin infections, a condition that affects millions of patients worldwide, without adding to the growing problem of antibiotic resistance. Galderma is looking forward to advancing the Aganocide programs for multiple indications."
Under the terms of the new agreement, which was initially signed in March 2009 for the research and development of impetigo and acne, Galderma has agreed to exercise its option to advance the clinical development program and will pay a $3.25 million continuation fee together with additional R&D funding in 2010 and 2011. NovaBay has the potential to receive up to $62 million in milestones from Galderma, and escalating double-digit royalties on net sales of products once commercialized.
Galderma will be financially responsible for all the development and clinical costs, and will reimburse NovaBay for the costs incurred in support of the collaboration. NovaBay retains the right to co-market products resulting from the agreement in Japan. In addition, NovaBay has retained rights in certain Asian markets outside of Japan, and has exclusive rights to promote the products developed under the agreement in hospital and other healthcare institutions in North America.
Impetigo Clinical Update (Partnered with Galderma)
Affecting over 1.4 million patients in the U.S., impetigo is a highly contagious superficial bacterial infection of the skin that affects mostly children. Most cases are caused by Staphylococcus aureus, Streptococcus pyogenes, or a mixture of both organisms. Methicillin-resistant S. aureus (MRSA) is being observed with increasing frequency in this population. Impetigo is currently being treated with antibiotic ointments, to which bacteria has developed resistance.
Recently, NovaBay announced top-line results from its randomized, sequential group, double-blind study designed to evaluate the efficacy and safety of three different strengths of NVC-422 topical gel in the treatment of impetigo. A total of 129 children in the age range 2-12 presenting with impetigo were randomized for treatment with NVC-422 topical gel three times daily for 7 days. Efficacy evaluations, compared to baseline, were conducted at the end of treatment and one week later. Clinical and bacteriological response rates for the three concentrations of drug applied ranged from 84% to 95% at end of treatment and at follow-up. These response rates were substantially higher than the response rate anticipated for placebo (30-50%). Notably, response rates for MRSA infections were 100% (10/10) across all treatment groups. The clinical and bacteriological response rates across the treatment groups suggested a dose response, although differences were not statistically significant. Infrequent adverse events were mild to moderate in severity and were predominantly local.
Acne Clinical Update (Partnered with Galderma)
Acne is the most common skin disease that affects people of all races and age groups, but it is most common in teenagers and young adults. An estimated 80 percent of all people between the ages of 11 and 30 suffer from outbreaks of acne at some point, and some people in their 40s and 50s are also affected. There is a clear need for more effective antimicrobial treatments than the currently available antibiotics.
Following a successful Phase 1 trial, NovaBay and Galderma are engaged in Phase 2 clinical research and will be evaluating various novel Aganocide formulations for treating acne.
Onychomycosis Update (Un-Partnered, In-House NovaBay Program)
Onychomycosis is the most common serious nail condition. Topical treatment of the infection is limited by the inability of currently available drugs to penetrate the human nail. According to Podiatry Today, over 35 million people in the United States have onychomycosis. Estimates indicate that up to 50% of those affected by the disease do not receive treatment. Systemic treatments represent well over 80% of the market today, but have potential severe liver toxicity issues, and have shown to have relapse rates of 40% or higher.
At the recent Infectious Diseases Society of America meeting, NovaBay presented data from a new study conducted using a novel in vitro infected human nail model to evaluate and confirm the ability of novel NVC-422 gel formulations and nanoemulsion lacquers to penetrate and kill fungi grown on the subungal side of the infected nail. The study was conducted by Mahmoud Ghannoum, PhD, at Case Western Reserve University's Center for Medical Mycology in Cleveland, OH.
These most recent data showed that NVC-422 was able to penetrate the nail and effectively eradicate T. mentagrophytes and T. rubrum, the fungi responsible for the majority of infections.
NovaBay has used other validated in vitro models and presented the results during the 47th IDSA Annual Meeting in 2009 ("In Vitro Evaluation of Stable Derivatives of the Chlorotaurines on Infected Human Nail Model as Potent Antifungal Agents for the Treatment of Onychomycosis"). Research for the study was conducted by MedPharm Ltd.
A Phase 1/2 clinical trial is being planned for early 2011.
I will add recent company postings so we can catch up and be up to date.
This will help monitor price fluctuations.
NovaBay Pharmaceuticals to Present at the 3rd Annual
LD MICRO Conference
Management to Present at 1:30 PM PST / 4:30 PM EST
EMERYVILLE, CA – December 1, 2010 – NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the LD MICRO Growth Conference on Thursday, December 9th, 2010 at the Luxe Sunset Bel Air in Los Angeles. The presentation is scheduled for 1:30 PM PST / 4:30 PM EST.
To arrange a meeting with management, please contact Adam Holdsworth at the Investor Relations Group, 212-825-3210, or e-mail adam@investorrelationsgroup.com.
yap, got mine too.
wasn't sure it would happen. it's a good sign for longs.
Hi 3,
any word on when the major stockholders are going to stop selling all their stock?
we would be at $6 if they didnt get so greedy.
tx
yes, all the way to ~$9 in 12mths.
3,000% run?
i'll have one too
there is share dillution...it's called 15B shares.
l2 has a wall of 2's.
us little guys can't take that down. even with the tiny 260M the company bought back.
I think there are way too many paid pumpers here. very obvious.
Please be careful all.
I meant new products. But I agree. Their projections are based on a few test stores. These tests usually occur in the optimal target market areas and it is very difficult to sustain such sales accross different markets.
Thanks
Do these guys have any new products out or new distribution?
Seems to me just a pump and dump PR scheme, if it even gets above 2 due to magical shares coming out of nowhere...dillution?
There is a wall at .0004
we'll need 10k websites to get out of this over .0005 anytime soon.
This wall and Georges snail paced business plan suck.
Seems their initiatives are only used for PR purposes.
I've been calling their offices for a while and nobody answers. No matter what extension I chose I got the same voicemail.
seems that this company is just in it for the stock giving them money?
not sure, any info?
I had made a similar post but now I can't find it.
not sure what's going on with this board.
anyone?
2M for me. how can we go up if VERT keeps pulling .0003 shares out of their stockings
i agree. looks like a long for me.
Pub sounds like a panacea right now. I'm in.
i couln't believe that either. was that u? j/k
i'm in @ 3. can this go to 4 or 5? my initial thought was 8, now looks like 7.
looks like too many shares @ 3. didn't stay at 4 for long each time this week.
lets see what the news does.
any ideas?
tx
numbers # logic vs street sense...ur probably right
enginerds like everyone else are only good at what they like to do.
wow, u guys really got me. I started trading last month and decided to pick up SMMT 2.5M @ 10. having a phd in engineering this stuff comes pretty easy. wasn't sure if i should go long or short on this one. Just trying to get some feedback cause of some concerns that were brought to my attention. from your post looks like i should have sold at 14.
have fun being mean.
later
I'm from so cal. my friend lives right down the streed from the corp address.
i'm in smmt. sounds like u've got problems with your positions.
there were 6 buys today. one for 5k shares. not so sure many are accumulating.
Does anybody know what this company does beside sell stocks?
I thought this was a shell company. not a scam?